CEA | Jotup

Plant Factory Market by Growing System, Facility Type, Light Type, Crop Type and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on:

Tuesday, August 31, 2021

By facility type, greenhouses are projected to dominate the market during the forecast period.

Key Points:

By facility type, greenhouses are projected to dominate the market during the forecast period.
Environmental elements such as temperature, light exposure, irrigation, fertilization, humidity, and ventilation can be controlled and monitored for optimal crop growth.
By light type, sunlight is projected to dominate the market during the forecast period.
As a result of the all-around development in plant factories, Europe has become a major market for plant factory.

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

Retrieved on:

Friday, August 27, 2021

The Boltbody ISAC platform combines a tumor-targeting antibody, a stable non-cleavable linker, and a proprietary immune stimulant.

Key Points:

The Boltbody ISAC platform combines a tumor-targeting antibody, a stable non-cleavable linker, and a proprietary immune stimulant.
Bolt will receive an upfront payment of US$5 million in cash from Innovent at signing and a possible future equity investment of up to US$10 million.
Furthermore, both Innovent and Bolt are eligible to receive additional milestones payments and royalties associated with the development and commercialization of products in each other's territories.
We look forward to collaborating with Innovent on the development of novel ISAC anti-cancer therapeutic candidates," said Randall Schatzman, Ph.D., CEO of Bolt.

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

Retrieved on:

Thursday, August 26, 2021

The Boltbody ISAC platform combines a tumor-targeting antibody, a stable, non-cleavable linker, and a proprietary immune stimulant.

Key Points:

The Boltbody ISAC platform combines a tumor-targeting antibody, a stable, non-cleavable linker, and a proprietary immune stimulant.
We look forward to collaborating with Innovent on the development of novel ISAC anti-cancer therapeutic candidates, said Randall Schatzman, Ph.D., CEO of Bolt Bio.
We are very excited about the potential for the Boltbody ISAC platform to generate best-in-class approaches treating multiple tumor types, said Dr. Yong Jun Liu, President of Innovent Biologics.
We look forward to working together with Bolt to bring innovative therapies to patients as soon as possible.

Hydrobuilder Holdings Appoints Chintan Patel as Chief Information Officer

Retrieved on:

Thursday, August 26, 2021

Hydrobuilder Holdings LLC (Hydrobuilder Holdings or the Company), a leading omnichannel platform serving the hydroponics, Controlled Environment Agriculture (CEA) and specialty agriculture industry, today announced the appointment of Chintan Patel as Chief Information Officer (CIO).

Key Points:

Hydrobuilder Holdings LLC (Hydrobuilder Holdings or the Company), a leading omnichannel platform serving the hydroponics, Controlled Environment Agriculture (CEA) and specialty agriculture industry, today announced the appointment of Chintan Patel as Chief Information Officer (CIO).
Prior to joining Hydrobuilder Holdings, Chintan served as Vice President of Information Technology Systems for SiteOne Landscape Supply, Inc. (NYSE: SITE), a North American wholesale distributor of landscape supplies.
We are pleased that Chintan has joined Hydrobuilder Holdings as our new Chief Information Officer.
We are delighted to be welcoming Chintan to our leadership team, said Markus Hockenson, Chief Executive Officer.

Noble Corporation Announces Divestment Of Four Jackups In Saudi Arabia, Resulting Updated 2021 Guidance And Preliminary 2022 Guidance

Retrieved on:

Thursday, August 26, 2021

The Company has combined the 2021 results for the Predecessor and Successor periods as non-GAAP measures when giving full-year 2021 guidance since we believe it provides the most meaningful basis to analyze our 2021 results.

Key Points:

The Company has combined the 2021 results for the Predecessor and Successor periods as non-GAAP measures when giving full-year 2021 guidance since we believe it provides the most meaningful basis to analyze our 2021 results.
Adjusted to exclude recognition of the non-cash intangible contract asset amortization of ~$51 million and ~$44 million in 2021 and 2022, respectively.
Without these adjustments, Revenue guidance ranges for 2021 and 2022 would be $819 million - $839 million and $931 million - $1,006 million, respectively.
Of the total calendar days available for our fleet in 2022, Noble assumes 86% of the days are operating days (excluding cold stacked rigs).

Heliospectra (publ) Half Year Report January-June 2021

Retrieved on:

Friday, August 20, 2021

Industry, LED, COVID, Growth, CEA, Lighting, Research, Nasdaq, SEK, Time, Goal, Solution, Horticulture, EBITDA, Technology, Agriculture

GOTHENBURG, Sweden, Aug. 20, 2021 /PRNewswire/ -- Heliospectra AB (publ) (Nasdaq First North Growth Market: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its' Half Year Reportfor January-June2021.

Key Points:

GOTHENBURG, Sweden, Aug. 20, 2021 /PRNewswire/ -- Heliospectra AB (publ) (Nasdaq First North Growth Market: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its' Half Year Reportfor January-June2021.
This figure includes the order cancellation from Nectar Farms, Australia, which was announced in April 2021.
Cash flow from investment activities mostly refers to capitalized work for own account in the form of product development.
Thank you for your continued support and we look forward to regularly updating you on our progress for the remainder of year.

First Ever Analysis of TCAR in Standard Surgical Risk Patients Demonstrates Clinical Benefits in Large Comparative Dataset

Retrieved on:

Wednesday, August 18, 2021

Society, Ninefold, CEA, GLOBE, CAS, CNI, Registry, Death, VAM, Risk, Patient, TCAR, SILK, Stroke, Dentistry, Medical device

SUNNYVALE, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, is pleased to highlight positive results from an independent analysis of standard surgical risk patients undergoing carotid endarterectomy (CEA) and transcarotid artery revascularization (TCAR) for atherosclerotic carotid disease. The analysis, presented today at the Society for Vascular Surgery 2021 Vascular Annual Meeting (VAM) in San Diego, California, is the first ever presentation of outcomes for TCAR in standard surgical risk patients.

Key Points:

The analysis, presented today at the Society for Vascular Surgery 2021 Vascular Annual Meeting (VAM) in San Diego, California, is the first ever presentation of outcomes for TCAR in standard surgical risk patients.
Over 20,000 standard surgical risk patients were included in the analysis (15,198 CEA and 5,066 TCAR) from the VQI CEA and carotid artery stent (CAS) registries over 4 years (August 2016 to September 2020).
The results for symptomatic and asymptomatic standard surgical risk patients undergoing CEA and TCAR for atherosclerotic carotid disease showed that TCAR had statistically equivalent stroke and death outcomes to CEA, while showing a ninefold reduction in cranial nerve injury (CNI) (2.7% vs 0.3%, p=
This first ever large-scale, standard surgical risk analysis demonstrates that TCAR delivers on that promise, said Erica Rogers, President and Chief Executive Officer ofSilk Road Medical.

urban-gro, Inc. to Speak and Exhibit at the International Cannabis Business Conference (ICBC)

Retrieved on:

Tuesday, August 17, 2021

Lafayette, Colorado--(Newsfile Corp. - August 17, 2021) - urban-gro, Inc. (NASDAQ: UGRO) ("urban-gro" or the "Company"), a fully integrated architectural, engineering and cultivation systems integration company for commercial cannabis and food-focused Controlled Environment Agriculture ("CEA") facilities, today announced that the company will speak and exhibit at the International Cannabis Business Conference (ICBC) on August 26-27, 2021 in Berlin, Germany.

Key Points:

Lucas Targos, Vice President of Facility Integration, will speak on "Cannabis Technology Revolutionizing an Emerging Industry"
To view an enhanced version of this graphic, please visit:
Lucas Targos, Vice President of Facility Integration, will speak on "Cannabis Technology Revolutionizing an Emerging Industry" at 2:20 pm CET.
"With the expansion of the medical cannabis market in Europe, facility owners, investors and regulators are very interested in the efficient, compliant production of safe medicinal cannabis products," notes Mr. Targos.
We integrate clients very early into the planning and design process to deliver facilities that are efficient and profitable.
His diverse background in cannabis and horticulture makes him an asset to the highly regulated cultivation solutions industry.

AeroFarms Provides Business Update

Retrieved on:

Monday, August 16, 2021

AeroFarms, a Certified B Corporation and leader in indoor vertical farming, today provided the following business update from Co-Founder and Chief Executive Officer, David Rosenberg.

Key Points:

AeroFarms, a Certified B Corporation and leader in indoor vertical farming, today provided the following business update from Co-Founder and Chief Executive Officer, David Rosenberg.
Upon the closing of the business combination, AeroFarms will become publicly traded on Nasdaq under the new ticker symbol "ARFM".
Spring Valley and AeroFarms anticipate that subsequent events and developments will cause Spring Valleys and AeroFarms assessments to change.
However, while Spring Valley and AeroFarms may elect to update these forward-looking statements at some point in the future, Spring Valley and AeroFarms specifically disclaim any obligation to do so.

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

Retrieved on:

Thursday, August 12, 2021

REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent business highlights.

Key Points:

REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent business highlights.
The monotherapy dose-escalation portion of the trial is proceeding on plan, with a further data update expected in the second half of 2021.
Bolt also remains on track to initiate the monotherapy Phase 2 dose-expansion cohorts and the dose-escalation of BDC-1001 in combination with an anti-PD-1 antibody in the second half of 2021.
Lossfrom Operations Loss from operations was $23.8 million for the quarter ended June 30, 2021 compared to $11.1 million for the same quarter in 2020.